biomodal Delivers the 6-Base Genome with a Powerful New Multiomic Solution, duet evoC
Retrieved on:
Monday, February 5, 2024
Research, Neurology, Genetics, Health Technology, Biometrics, Biotechnology, Health, Science, Oncology, Other Science, Liquid biopsy, Workflow, Breast cancer, Phenotype, DNA, Division, Gene, Biomarker, Literature, Genetic distance, Head, RNA-Seq, Gene expression, GEO, Foundation (nonprofit), Methylation, Q40, Royal College of Pathologists, Genotype, Disease, 5-Methylcytosine, Genomics, Biology, ATAC, FRSC, University of British Columbia, Chromatin, Medicine, University, Neoplasm, Cancer, Nucleic acid thermodynamics, Genome, BCH, Vanderbilt University Medical Center, Medical imaging
biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC).
Key Points:
- biomodal, an omics-based life sciences technology and analytics company, today announced it is delivering the 6-base genome to customers with the launch of duet multiomics solution evoC (duet evoC).
- The advanced 6-base genome data enables the exploration of epigenetic mechanisms of gene regulation through methylation and hydroxymethylation.
- “Delivering the 6-base genome with the launch of duet evoC is a revolutionary development for researchers in the fields of oncology, neurology, ageing, and functional genomics.
- duet evoC is advancing our mission to help scientists reveal new data and insights that will evolve solutions for early disease detection, treatment, and monitoring,” said Peter Fromen, chief executive officer at biomodal.